Kristopher Swiger

Instructor

20132017
If you made any changes in Pure, your changes will be visible here soon.

Fingerprint Dive into the research topics where Kristopher Swiger is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 3 Similar Profiles
Hydroxymethylglutaryl-CoA Reductase Inhibitors Medicine & Life Sciences
LDL Cholesterol Medicine & Life Sciences
Cognition Medicine & Life Sciences
clopidogrel Medicine & Life Sciences
Lipids Medicine & Life Sciences
Databases Medicine & Life Sciences
Amyloidosis Medicine & Life Sciences
Dementia Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 2013 2017

Cardiomyopathic Toxicity From Chemotherapy: Is There an Opportunity for Preemptive Intervention?

Swiger, K., Singh, J. & Lenihan, D. J., Mar 1 2017, In : Current Treatment Options in Cardiovascular Medicine. 19, 3, 20.

Research output: Contribution to journalReview article

Left Ventricular Dysfunction
Primary Prevention
Secondary Prevention
Drug Therapy
Heart Failure

Current Concepts of Cardiac Amyloidosis: Diagnosis, Clinical Management, and the Need for Collaboration

Ritts, A. J., Cornell, R. F., Swiger, K., Singh, J., Goodman, S. & Lenihan, D. J., Apr 1 2017, In : Heart Failure Clinics. 13, 2, p. 409-416 8 p.

Research output: Contribution to journalReview article

Amyloidosis
Genetic Testing
Biomarkers
Biopsy
Therapeutics

PCSK9 inhibitors and their role in high-risk patients in reducing LDL cholesterol levels: Alirocumab

Dahagam, C., Goud, A., Abdelqader, A., Hendrani, A., Feinstein, M. J., Qamar, A., Joshi, P. H., Swiger, K., Byrne, K., Quispe, R., Jones, S., Blumenthal, R. S. & Martin, S., Mar 1 2016, In : Future Cardiology. 12, 2, p. 149-157 9 p.

Research output: Contribution to journalArticle

LDL Cholesterol
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Monoclonal Antibodies
Outcome Assessment (Health Care)
Diet

PCSK9 inhibitors and their role in high-risk patients in reducing LDL cholesterol levels: Evolocumab

Dahagam, C., Goud, A., Abdelqader, A., Hendrani, A., Feinstein, M. J., Qamar, A., Joshi, P. H., Swiger, K., Byrne, K., Quispe, R., Jones, S., Blumenthal, R. S. & Martin, S., Mar 1 2016, In : Future Cardiology. 12, 2, p. 139-148 10 p.

Research output: Contribution to journalArticle

Hydroxymethylglutaryl-CoA Reductase Inhibitors
LDL Cholesterol
Hyperlipoproteinemia Type II
Life Style
Monoclonal Antibodies

Plasma hepatocyte growth factor is a novel marker of AL cardiac amyloidosis

Swiger, K., Friedman, E. A., Brittain, E. L., Tomasek, K. A., Huang, S., Su, Y. R., Sawyer, D. B. & Lenihan, D. J., Oct 1 2016, In : Amyloid. 23, 4, p. 242-248 7 p.

Research output: Contribution to journalArticle

Hepatocyte Growth Factor
Amyloidosis
Amyloid
Light
Cardiomyopathies